Novo Nordisk has launched its Wegovy weight-loss pill in the US at significantly lower prices than injections.
The once-daily pill is the first GLP-1 tablet approved, offering a needle-free alternative for obesity treatment.
Cash-paying patients can access starting doses for $149 a month, far below typical injectable prices.
Analysts at UBS said pricing was lower than expected, accelerating competition.
The launch challenges rivals including Eli Lilly, which also plans an obesity pill.
Wegovy pills are available at major US pharmacies and telehealth platforms, with wider rollout expected soon.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
